[Selectivity of alpha 2-adrenergic agonists for the imidazoline-guanidine and alpha 2-adrenergic receptors].
Imidazolines have been proposed as highly selective drugs for alpha 2-adrenergic receptors. However, we have recently showed that the imidazoline ligand 3H-RX 781094 (idazoxan) binds to both alpha 2-receptors and imidazoline guanidinium receptive substance (IGRS) in rabbit renal proximal tubule. Binding of 3H-RX 781094 to the purified basolateral membranes (15-fold enriched in Na-KATPase activity) was rapid (t 1/2 = 5 mn.) reversible (t 1/2) = 4 mn.), saturable and of high affinity. Scatchard analysis of equilibrium binding data showed that 3H-RX 781094 labels 566 +/- 118 fmol/mg of proteins of binding sites with an apparent dissociation constant (Kd) of 1.45 +/- 0.14 nM. On the other hand, the non imidazoline ligand 3H-rauwolscine binds only to the alpha 2-adrenergic receptors with a maximal density of 155 +/- 28 fmol/mg of protein and a Kd of 11.5 +/- 1.5 nM. In order to define the relative affinity of the alpha-2-agonists, clonidine, rilmenidine and guanfacine for the two classes of receptors, we performed competition studies of the alpha 2-antagonists 3H-RX 781094 (imidazoline) and 3H-rauwolscine (non imidazoline) binding to basolateral membranes from rabbit proximal tubule. The order of potency for inhibition of the two radioligand binding was rilmenidine greater than clonidine greater than guanfacine for 3H-RX 781094 and clonidine greater than guanfacine greater than rilmenidine for 3H-rauwolscine. Therefore, rilmenidine displayed a higher affinity for IGRS than for alpha 2 adrenergic receptors; on the other hand, clonidine and guanfacine preferentially interact with alpha 2 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Lachaud
V
V
U 7 INSERM/UA 318 CNRS, département de pharmacologie, hôpital Necker, Paris.
Coupry
I
I
Podevin
R A
RA
Koenig
E
E
Parini
A
A
D000316:Adrenergic alpha-Agonists / Q000378:metabolism*; D000317:Adrenergic alpha-Antagonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D003000:Clonidine / Q000378:metabolism; D004146:Dioxanes / Q000037:antagonists & inhibitors / Q000378:metabolism; D016316:Guanfacine; D006146:Guanidines / Q000378:metabolism; D019329:Idazoxan; D007687:Kidney Tubules, Proximal / Q000378:metabolism; D008297:Male; D010080:Oxazoles / Q000378:metabolism; D010648:Phenylacetates / Q000378:metabolism; D011817:Rabbits; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D000077769:Rilmenidine; D015016:Yohimbine / Q000037:antagonists & inhibitors / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D006146:Guanidines; D010080:Oxazoles; D010648:Phenylacetates; D011942:Receptors, Adrenergic, alpha; D015016:Yohimbine; D016316:Guanfacine; D003000:Clonidine; D000077769:Rilmenidine; D019329:Idazoxan
Sélectivité des agonistes alpha 2-adrénergiques pour les récepteurs imidazolinique-guanidiniques et alpha 2-adrénergiques.